Comparison Of The Two Types Of Hemostasis Management Effectiveness : Thromboelastometry (Rotem) Guided Management And Conventional Method In Newborn Congenital Cardiac Surgery Patients
NCT ID: NCT06166940
Last Updated: 2023-12-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2022-03-01
2023-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Anesthesia induction conducted with midazolam, ketamine, fentanyl, and rocuronium bromide; and antifibrinolytic (tranexamic acid) infusion was used during operation till the closure of skin. Anesthesia and cardiopulmonary bypass(CPB) anesthesia was maintained with remifentanil, midazolam, ketamine and rocuronium, and sevoflurane -not during bypass. Size-adapted bypass circuits and membrane oxygenators (FX05 oxygenators) were used. Total priming volume for the bypass circuit was 250 - 400 ml, consisting of red blood cell (RBC), fresh frozen plasma (FFP), Isolyte-S solution, mannitol, sodium bicarbonate, tranexamic acid, prednisol, and antibiotic. Anticoagulation during CPB was managed with 350 U/kg unfractioned heparin (Novo-Heparin) and additional boluses of 50 U/kg, as needed, to maintain an activated clotting time (ACT) of at least 450s. Heparin anticoagulation was antagonized with 3,5 mg/kg protamine.
Red blood cell concentrates were transfused to maintain the haematocrit at 28 - 32% during cardiopulmonary bypass (CPB). Bypass was conducted under mild (core temperature 32°C ) and moderate (core temperature 28 °C) hypothermia. Myocardial protection was achieved with cold intermittent blood cardioplegia (20 ml/kg), which was prepared during CPB by adding buffered del nido solution (Plasma-Lyte A) in the ratio 1:4 to whole blood obtained from the arterial line. The cardioplegia solution was kept at 6°C before infusion. Blood sample for running ROTEM analysis were taken just before weaning CPB, when the core temperature of patients were 36-37 °C. MUF was performed after weaning from CPB and 5-10 minutes before protamine administration, with a target haematocrit of 35-40%. After heparin antagonization, RBC transfusions applied with a target haematocrit of 35-40 % for non-cyanotic patients, and 40-45% for cyanotic patients.
We collected data on the following subject characteristics: height (cm); weight (kg); age (days); gender; presence of cyanosis; presence of ay genetic disorder; Aristotle score (1,5-25); duration of the surgical procedure (min); CPB time (min); aortic cross clamp time (min); the lowest core temperature during CPB; total amount of blood products transfused after CPB intraoperatively (ml/kg), including red blood cell concentrates, FFP, platelet concentrates, cryoprecipitate, and fibrinogen concentrates; total amount of blood products transfused after operation up to 24 h after admission to the Pediatric Cardiac Intensive Care Unit (PCICU) (ml/kg); total amount of chest tube drainage after operation up to 24 h after PCICU admission (ml/kg); 28 day survival; extracorporeal membrane oxygenator (ECMO) application; and need for peritoneal dialysis.
In all patients, routine blood samples for hemoglobin (Hb), haematocrit (Hct), prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), platelet count; renal function tests urea and creatinine were collected preoperatively. Hb, Hct, PT, INR, aPTT, platelet count, urea and creatinine were also analyzed on the first postoperative morning.
We conducted thromboelastometry in the operating theatre (OR) using the ROTEM device. Four assays-EXTEM, INTEM, FIBTEM, and HEPTEM were tested in citrated whole blood. Because the patients were still under heparin effect when the samples were taken, we made transfusion adjustments according to EXTEM and FIBTEM test results. Since we got the EXTEM, FIBTEM A5 results as soon as heparin antagonization was complete, we transfused the blood products according to the results. We also collected those data.
The primary outcome was the proportion of perioperative transfusion (intraoperatively and in the PCICU) in the ROTEM group and in the conventional group. The secondary outcomes are postoperative chest tube drainage up to 24 hours; need for peritoneal dialysis. The other analyses have mainly a descriptive purpose.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Insignificant bleeding-normal ROTEM; no transfusions
2. Insignificant bleeding-abnormal ROTEM; no transfusions
3. Significant bleeding-normal ROTEM; surgical reevaluation
4. Significant bleeding-abnormal ROTEM; transfusion of blood products as indicated by:
1. FIBTEM A5 \<9 mm -fibrinogen concentrate or cryoprecipitate
2. 9mm ≤ FIBTEM A5 \<13mm and or EXTEM CT \> 80 seconds fibrinogen concentrate or cryoprecipitate and significant bleeding still continued with EXTEM A5 \< 35 mm - platelet concentrate
3. FIBTEM A5 \>13mm and EXTEM A5 \< 35 mm -platelet concentrate
4. After transfusions if the bleeding was still continuing, while surgical reevaluation was in progress, we gave fibrinogen concentrate to replace the lost fibrinogen with the ongoing bleeding. At the same time to verify the treatment effect and control heparin reversal, a second set of INTEM, HEPTEM, EXTEM and FIBTEM analyses were also performed during wound closure. ACT was tested in all patients to control for heparin reversal. If patients had both a pathological ACT and ROTEM (CTIN/ CTHEP ratio ≥ 1,25) protamine was administered first. After fibrinogen and platelet transfusions, if INTEM CT \> 280 seconds and HEPTEM CT \> 280 seconds with continuing bleeding FFP were given.
Blood transfusion after paediatric intensive care unit (PCICU) admission was managed without ROTEM guidance by paediatric cardiac surgeons and intensivists.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Conventional Management
ROTEM Guided Management
ROTEM guided management of hemostasis after CPB
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ROTEM Guided Management
ROTEM guided management of hemostasis after CPB
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* the newborns whose records are missing were excluded
0 Days
30 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Başakşehir Çam & Sakura City Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Basaksehir Cam and Sakura City Hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023.11.11
Identifier Type: -
Identifier Source: org_study_id